MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases

Daniela Claessens, Parul Ichhpujani, Rohan Bir Singh, Daniela Claessens, Parul Ichhpujani, Rohan Bir Singh

Abstract

Purpose: Macular diseases often lead to metamorphopsia, which is traditionally tested using the Amsler grid. This study evaluates a novel method for assessing metamorphopsia, based on the software AMD-A Metamorphopsia Detector, application MacuFix®.

Methods: In this observational study, the usability of a new smartphone-based testing method to assess metamorphopsia was evaluated in 45 patients experiencing metamorphopsia in at least one eye using the questionnaire "System Usability Score (SUS)." Additionally, the diagnostic adherence of self-monitoring with the Amsler grid was compared to self-monitoring with the novel software MacuFix®.

Results: The average score of the SUS questionnaire in this study was 76.7 ± 15.5, corresponding to the "good" score on the grading scale. The average interval between two home administered tests was significantly shorter (6 days) when the application was used as compared to using the Amsler grid (19 days). The odds ratio of the frequency of patients using the application to the patients using the home test was 4.

Conclusion: MacuFix® application can help in effective home monitoring of macular function as high user satisfaction and increased testing frequency was observed in its use in patients with macular diseases.

Trial registration: ClinicalTrials.gov NCT04347564.

Keywords: Adherence; Age-related macular degeneration; Diabetic macular edema; Metamorphopsia; Smartphone-based application; Usability.

Conflict of interest statement

Parul Ichhpujani and Rohan Bir Singh certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. Daniela Claessens is co- owner and medical advisor for app4eyes GmbH&CoKG and holds a patent (German Patent DE102019205318).

© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Figures

Fig. 1
Fig. 1
MacuFix used on a smartphone
Fig. 2
Fig. 2
SD-OCT of the left eye of Subject No. 45 with medium drusen and no pigmentary abnormalities and an example of the distortion difference 1: The upper left quadrant contains lines that are more distorted than those in the remaining three quadrants
Fig. 3
Fig. 3
SD-OCT Subject No. 14 left eye and Macufix distortion difference 2
Fig. 4
Fig. 4
SD-OCT Subject No. 10 left eye and MacuFix distortion difference 4
Fig. 5
Fig. 5
SD-OCT Subject No. 8 left eye and MacuFix distortion difference 5

References

    1. Tripathy K, Salini B. Amsler Grid (2021). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from:
    1. Marmor MF. A brief history of macular grids: from Thomas Reid to Edvard Munch and Marc Amsler. Surv Ophthalmol. 2000;44(4):343–353. doi: 10.1016/s0039-6257(99)00113-7.
    1. Schuchard RA. Validity and interpretation of Amsler grid reports. Arch Ophthalmol. 1993;111(6):776–780. doi: 10.1001/archopht.1993.01090060064024.
    1. Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E, Alster Y, Rafaeli O, Avni I, Yassur Y. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology. 2003;110(5):966–970. doi: 10.1016/S0161-6420(03)00074-5.
    1. Bartlett H, Davies LN, Eperjesi F. The macular mapping test: a reliability study. BMC Ophthalmol. 2005;5:18. doi: 10.1186/1471-2415-5-18.
    1. Kampmeier J, Zorn MM, Lang GK, Botros YT, Lang GE. Vergleich des Preferential-Hyperacuity-Perimeter (PHP)-Tests mit dem Amsler-Netz-Test bei der Diagnose verschiedener Stadien der altersbezogenen Makuladegeneration [Comparison of Preferential Hyperacuity Perimeter (PHP) test and Amsler grid test in the diagnosis of different stages of age-related macular degeneration] Klin Monbl Augenheilkd. 2006;223(9):752–756. doi: 10.1055/s-2006-926880.
    1. Claessens D, Schuster AK. Correlation of quantitative metamorphopsia measurement and central retinal thickness in diabetic macular edema and age-related exsudative macular degeneration. Klin Monbl Augenheilkd. 2019;236(7):877–884. doi: 10.1055/s-0043-125080.
    1. Claessens D, Schuster AK, Krüger RV, Liegl M, Singh L, Kirchhof B (2020)Test-Retest-reliability of computer-based metamorphopsia measurement in macular diseases. Klin Monbl Augenheilkd. (Epub ahead of print)
    1. Bangor A, Kortum PT, Miller JT. An empirical evaluation of the system usability scale. Int J Hum-Comput Interact. 2008;24(6):574–594. doi: 10.1080/10447310802205776.
    1. Brooke J. SUS-A quick and dirty usability scale. In: Corporation DE, editor. Usability evaluation in industry. London: CRC Press; 1996.
    1. Muether PSHR, Hermann MM, Kirchhof B, Fauser S. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:453–458. doi: 10.1007/s00417-012-2038-0.
    1. Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012;153(4):678–686. doi: 10.1016/j.ajo.2011.09.013.
    1. Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, et al. Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS. Ophthalmol Retina. 2018;2(6):539–549. doi: 10.1016/j.oret.2017.09.017.
    1. Wintergerst MWM, Bouws J, Loss J, Heimes B, Pauleikhoff D, Holz FG, et al. Reasons for delayed and discontinued therapy in age-related macular degeneration. Ophthalmologe. 2018;115(12):1035–1041. doi: 10.1007/s00347-017-0610-z.
    1. Achard OA, Safran AB, Duret FC, Ragama E. Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol. 1995;120(3):322–329. doi: 10.1016/S0002-9394(14)72162-2.
    1. Parkes L, Lund J, Angelucci A, Solomon JA, Morgan M. Compulsory averaging of crowded orientation signals in human vision. Nat Neurosci. 2001;4(7):739–744. doi: 10.1038/89532.
    1. Domalpally A, Clemons TE, Bressler SB, Danis RP, Elman M, Kim JE, et al. Imaging characteristics of choroidal neovascular lesions in the AREDS2-HOME study: report number 4. Ophthalmol Retina. 2019;3(4):326–335. doi: 10.1016/j.oret.2019.01.004.
    1. Ehlken C, Helms M, Bohringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018;12:13–20. doi: 10.2147/OPTH.S151611.
    1. Holz FG, Tadayoni R, Beatty S, Berger AR, Cereda MG, Hykin P, et al. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye (Lond) 2016;30(8):1063–1071. doi: 10.1038/eye.2016.90.
    1. Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. doi: 10.1136/bjophthalmol-2014-305327.
    1. Ulbig M, Höh H, Schmickler S, Wolf A, Dimopoulos S, Lorenz K, et al. Treatment reality with ranibizumab in clinical routine use for patients with diabetic macular edema: 1-year results of the German POLARIS cohort. Ophthalmologe. 2019;116(7):631–639. doi: 10.1007/s00347-018-0793-y.
    1. Holz FG, Johnson KT, Bauer-Steinhusen U, Rech C, Machewitz T, Muller S, et al. ANDROMEDA-an investigation of factors influencing the adherence of patients with neovascular age-related macular degeneration using the newly developed patient questionnaire LAF-IVT. Ophthalmologe. 2019;117(8):765–774. doi: 10.1007/s00347-019-01005-4.
    1. Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J. Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies. Adv Ther. 2020;37(1):300–315. doi: 10.1007/s12325-019-01147-6.
    1. Angermann R, Rauchegger T, Nowosielski Y. Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2119–2125. doi: 10.1007/s00417-019-04414-y.
    1. Parikh R, Avery RL, Saroj N, Thompson D, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept or ranibizumab. JAMA Ophthalmol. 2019;137(8):914–920. doi: 10.1001/jamaophthalmol.2019.1947.
    1. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi: 10.1016/j.ophtha.2012.09.006.
    1. Krüger R, Claessens D. Reliability of a novel computer-based metamorphopsia categorization tool. Baltimore: Association for Research and Vision in Ophthalmology; 2020.
    1. Meyer CH, Lapolice DJ. Computer-based visual evaluation as a screening tool after intravitreal injections of vascular endothelial growth factor inhibitors. Ophthalmologica. 2008;222(6):914–920. doi: 10.1159/000151246.
    1. Cordes A, Strobel A, Meyer CH, Ender F, Schrage N. Visual self-assessment with the ACTO test during follow-up of AMD patients after intravitreal injections. Ophthalmologe. 2009;106(9):775–782. doi: 10.1007/s00347-009-1959-4.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться